We provide initial evidence that Notch inhibition using a gamma secretase inhibitor (GSI) changes multiple aspects of the cellular metabolome in brain tumors. These changes in glioblastoma neurospheres included reduced intracellular glutamate, which was not seen when treating with other chemotherapeutic agents, or in human neural stem cells after Notch inhibition. Alterations in glutamate metabolism may represent a mechanism by which Notch modulates brain tumor growth and have diagnostic or therapeutic utility.
, and one such pathway is Notch.
Notch regulates numerous processes during embryonic and adult development, 4 including neural stem cell biology, 5 and its oncogenic role has been demonstrated in many tumors outside the brain 6 as well as in GBM 7 . The importance of understanding the effect of key oncogenes on the cellular metabolome in cancer is becoming increasingly appreciated 8 .
Recent studies suggest that Notch can regulate cellular metabolism in normal tissues [9] [10] [11] , and in some tumors outside the brain such as leukemia 12 or breast cancer 13 . However, little is known about the effects of Notch on the metabolism of brain tumors including GBM.
We therefore examined the effects of Notch inhibition on the global metabolome in GBM neurospheres. Prior studies have shown that pharmacological inhibition of the enzyme gamma-secretase, responsible for terminal activating cleavage of the Notch receptor, effectively targets the stem-like cell population in GBM 14 . The gamma-secretase inhibitor MRK003 was therefore used to treat GBM neurospheres sensitive to Notch blockade in terms of pathway suppression, as well as insensitive control lines. Inhibition of Notch activity caused a range of metabolic changes in the GBM cells as measured by high-resolution proton nuclear magnetic resonance spectroscopy ( 1 H-NMR), including phosphocholine as well as metabolites associated to glycolysis and glutaminolysis. Given the previously reported important role of glutamate in gliomagenesis 27 we decided to focus our studies on this metabolite and found decreased levels of intracellular glutamate in glioma cells after Notch blockade. This was not observed after treatment with pharmacological compounds Accepted Article 7 target genes (HES1 and HEY1) expression but only low to moderate cell death. With this treatment regime, we aimed to minimize secondary effects on the metabolome introduced through cell degradation.
Extraction and quantification of metabolites from in vitro cultures using high resolution proton nuclear magnetic resonance spectroscopy ( 1 H-NMR)
Cells were harvested, washed twice in 1xPBS (Life Technologies) and quantified using Trypan blue (#T8154, Sigma-Aldrich) exclusion assay (3 independent counts). A minimum of 7*10 6 cells per sample were used for each extraction and total cell numbers where used to normalized between MRK003 and DMSO counterparts. The methanolchloroform-water (1/1/1, v/v/v, all Sigma-Aldrich) dual phase cell extraction protocol was applied to obtain water and lipid-soluble metabolites as previously described 18 . The Avance 500 spectrometer operating at 11.7 T using a 5-mm HX inverse probe run at 25°C as previously described 18 . The fully relaxed 1 H-NMR data were post-processed and metabolites quantified through peak integration using Mestrenova v10.0 (Mestrelab Research, CA, USA). Functional Annotation, as previously described 20 . Similarly, all processes for gene annotation, raw expression data and MIAME (Minimal Information about a Microarray Experiment) have been described by our lab before 19 . We considered genes with a false discovery rate of <5% as differentially regulated. The data can be accessed through the NCBI GEO data portal under http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71769.
Targeted gene expression analyses and Western blot
The relative abundance of gene transcripts was determined using SYBR-green based ddCt-method on an IQ Determination of WNT/beta-catenin pathway activity WNT/beta-catenin pathway inhibition through LGK974 was confirmed through bioluminescence-based quantification of occupied putative beta-catenin T cell factor/lymphoid enhancer factor (TCF/LEF)-binding sites using the stable integration of 7TFP firefly luciferase reporter as described before 24 . Infectious lentiviral particles were generated using the 3 rd generation lentiviral packaging system and stable integration was selected through puromycin (Sigma-Aldrich) resistance at a concentration of 2ug/ml. 
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Results:
Altered metabolic profiles in glioma neurospheres after Notch suppression It has been shown that while some GBM are sensitive to GSIs, others are resistant to Notch blockade 26 . mRNA levels of the canonical Notch pathway targets HES1 and HEY1
were measured to confirm sensitivity or resistance in five glioma lines. Four of these were originally derived as neurospheres, while U87 was continuously passaged as neurospheres in serum free media for these studies and designated as U87NS. Significant suppression of mRNA levels for several direct transcriptional targets of Notch were achieved in the GBM1, GBM10 and GBM14 lines, but not in U87NS or 040922 cells ( Figure 1A , p≤0.05). Based on this, we classified GBM1, GBM10, and GBM14 as MRK003 sensitive, with U87NS and 040922 designated MRK003 insensitive.
High resolution proton nuclear magnetic resonance spectroscopy ( 1 H-NMR) was used to compare metabolic changes in MRK003 sensitive and insensitive lines. While this technique allows for precise identification and quantification, it requires extremely large numbers of cells, thus the initial survey was performed on only the two fastest growing lines in each group, GBM1 and U87NS. The levels of GSI used for these studies resulted in a modest induction of apoptosis for GBM1 and had no effect AnnexinV in the other tested cell lines. (Figure 1B , p≤0.05).
We identified a broad range of metabolites with characteristic peak formations of
glutamine (Gln) at 2.41ppm (M), glutathione (GSH) at 2.50ppm (M), total creatine (tCre) at 3.03ppm (D), free choline (fCho) at 3.18ppm (S), phosphocholine (PC) at 3.22ppm (S), glycerophosphocholine (GPC) at 3.24ppm (S), glycine (Gly) at 3.55ppm (S) and myo-inositol (myo) at 4.05ppm (M). Representative findings are shown in Figure 2A , and the summary of 12 three independent experiments in each of the two lines in Figure 2B . Interestingly, while a number of metabolite levels decreased after Notch blockade in the sensitive GBM1 cells, no corresponding decreases were seen in MRK003 insensitive U87NS except for myo-inositol ( Figure 2B ). Significant decreases were noted in glutamate, glutamine, free choline, phosphocholine after Notch pathway inhibition. Myo-inositol levels also decreased in the GBM1 and significantly reduced in U87NS cells after GSI treatment. Due to technical issues in one GBM1 repetition only two of the three independent samples could be quantified for this metabolite, and therefore no statistical comparison of myo-inositol was performed in these cells. Interestingly, while no other significant decreases in metabolite levels were seen in U87NS cells, threonine and lactate levels were significantly increased.
Reduction of glutamate after Notch inhibition
We focused on changes to glutamate, and Figure 3A shows a more detailed view of a representative spectra of this region, with a 36% mean reduction (p≤ 0.05) in GBM1 cells as compared to a non-significant 7% increase in U87NS cells after Notch inhibition. To verify this observation and extend it to additional lines, we used an ELISA-based method based on oxidation of glutamate, which was more easily performed on small samples. This confirmed that Notch pathway suppression reduced intracellular glutamate levels by 50% and 26% in the GSI sensitive lines GBM1 and GBM10 (p≤ 0.05).No glutamate reduction was noted in the insensitive U87NS and 040922 neurospheres ( Figure 3B ). In addition, while MRK003
inhibited Notch in human fetal cortical neurospheres, it did not reduce levels of intracellular glutamate ( Figure 3C ), suggesting that the observed Notch-glutamate interplay is differentially regulated in non-neoplastic neural stem cells.
Treatment with other chemotherapeutics did not reduce glutamate
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To determine if the observed glutamate reduction might be a general consequence of treatment, we examined the effect of other pharmacological agents on glutamate levels. The standard alkylating agent temozolomide (TMZ) and the mTOR inhibitor INK-128/MLN0128
(MLN) were tested on the MRK003 sensitive cell lines GBM1 and GBM10. Both TMZ and MLN caused a profound decrease in cellular growth ( Figure 4A ), and after 48 hours apoptosis in GBM1 was induced to a degree similar to that seen with MRK003, but no corresponding glutamate reduction was detected in these samples ( Figure 4B ). Thus chemotherapeutic growth inhibition and increased apoptosis is not always associated with glutamate alterations in glioma neurospheres.
We also examined if other pathways important in non-neoplastic and glioma stem cells might regulate glutamate. A number of groups have shown that WNT signaling blockade depletes stem-like glioma cells 28 . We have recently shown that the porcupine inhibitor LGK974, which targets WNT signaling by modulating ligand processing, can also inhibit the pathway and reduce survival in glioma neurospheres 25 . For these LGK974 studies, LN229 cells were used instead of GBM10, as LN229 is characterized by higher WNT activity similar to that seen in the upper range of snap frozen GBM specimens 25 . Inhibition of the pathway after LGK974 administration was confirmed by reduction in luciferase WNT reporter signals, with no corresponding effects on glutamate levels ( Figure 4C ).
Notch blockade alters expression of multiple regulators of glutamate homeostasis
In order to determine the mechanism by which Notch was altering glutamate levels, we examined global transcriptomes from MRK003 sensitive GBM1, GBM10 and GBM14 cells after 2µM MRK003 treatment. This identified a number of dysregulated genes important for glutamate homeostasis, which are listed in Figure 5A . To confirm this, we performed 
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This article is protected by copyright. All rights reserved. , and is known to be positively associated to rapid cancer cell proliferation 37 . Furthermore, we found lactate, an indicator of active glycolysis, to be increased after treatment with the Notch inhibitor in both glioma subgroups. This is concordant with very recent discoveries that Notch stimulates cellular anaerobic glucose metabolism in breast cancer 13 and during macrophage activation 38 .
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Besides these alterations, we found a significantly different response in the two glioma groups after drug treatment in terms of intracellular glutamine (gln) and glutamate (glu), as we detect significant lower levels of these two metabolites in MRK003 sensitive GBM1 but not in MRK003 insensitive U87NS after treatment. We focused in particular on changes to glutamate, given the many prior studies implicating it in the biology of brain tumors 27 and confirmed its reduction after Notch blockade with oxidation based quantifications. These changes may be linked to increased differentiation of the tumor.
It has previously been shown that differentiated glioma cells possess lower levels of glutamate as compared to stem-like GBM cells 39 . This glutamate accumulation is thought to possibly be due to overactive glutamate uptake mediated through the members of the soluble carrier (SLC) membrane transporters family. 43 However, further studies are needed to determine whether the lowered glu level in our cells is a consequence of altered consumption or production.
Regardless of the mechanism by which glu is regulated by Notch, it appears to be a promising therapeutic target. We found that Notch blockade suppressed transcript levels of cardinal glutaminolysis regulator glutaminase (GLS). GLS is known to promote cancer cell proliferation 44, 45 and its suppression can impair tumor growth. Previously, genetic GLS suppression slowed GBM growth, and pharmacological suppression with BPTES preferentially acted on glioma cells with mutant isocitrate dehydrogenase 1 (IDH1) 46 . We This treatment led to minimal induction of apoptosis in GBM1 (21% to 27% AnnexinV positive cells) and had no effect on GBM10, U87NS and 040922 (B, p-value≤0.05). Supporting Data File S1: Short tandem repeat profiles of cell lines used in this study.
Supporting Data File S2: Primer sequences used for RT qPCR in this study.
Page 24 of 30
John Wiley & Sons, Inc.
International Journal of Cancer
Accepted Article
Figure 1: Glioma cell lines with different sensitivity to Notch blockade with MRK003: Confirmation of successful suppression of Notch signaling through inhibition of transcription of canonical pathway targets HES1 and HEY1 distinguishes between MRK003 sensitive (GBM1, GBM10 and GBM14) and insensitive (U87NS and 040922) cells (A, p-value≤0.05). This treatment led to minimal induction of apoptosis in GBM1 (21% to 27% AnnexinV positive cells) and had no effect on GBM10, U87NS and 040922 (B, p-value≤0.05).
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